Compare Moderna, Inc. (MRNA) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs TORM plc — how do they compare? Moderna, Inc. trades at $224.78 (market cap $78.65B), while TORM plc trades at $40 (market cap $4.12B). The key difference: Moderna, Inc. is far larger — about 19.1× TORM plc's market cap, and TORM plc pays a 11.03% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and TORM plc for 23 Days on average.
| MRNA | TRMD | |
|---|---|---|
Market Cap | $78.65B | $4.12B |
Volume | 37,373,437 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $203.46 | $41.05 |
52-Week Low | $22.36 | $19.39 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $74.80B | $4.83B |
Dividend Yield | — | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
TRMD trades at $40.19, up 3.26% today, with a bullish technical outlook from moving averages. The stock shows strong profitability with a 35.52% net income margin and attractive valuation ratios, including a P/E of 6.59. Recent earnings saw a Q4 2025 beat but Q1 and Q2 2026 misses, while Q3 2026 results are pending. A $2.40 dividend is scheduled for September 2026. Cash flow improved to a net positive $6M in 2026 from a negative $113.8M in 2025.
The outlook is positive given robust fundamentals and unanimous analyst buy ratings, though risks include spot rate volatility and insider selling. Revenue growth and dividend yield present opportunities, but investors should monitor freight rate trends and execution on future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
